 phase iii comparison doxorubicin bolu versu infus patient soft-tissu sarcoma southwest oncolog group studi soft-tissu sarcoma group uncommon malign uniform manner studi impact schedul respons rate toxic patient metastat soft-tissu sarcoma two-drug combin doxorubicin dacarbazin patient bolu therapi doxorubicin dose dacarbazin dose day patient infusion therapi doxorubicin dacarbazin continu intraven infus hour day patient chemotherapi week uniqu featur cooper group protocol provis surgic resect residu diseas patient partial respons stabl diseas chemotherapi similar overal respons rate treatment arm complet respons rate treatment arm patient bolu therapi median respons durat month complet remiss month partial remiss patient infusion therapi median respons durat month complet remiss month partial remiss examin dose intens treatment arm weak doxorubicin dose-respons relationship differ median surviv time treatment arm bolu therapi month infusion therapi month analysi toxic effect infusion therapi signific reduct cardiac toxic event clinic event nausea emesi infusion therapi patient elig cytoreduct surgeri chemotherapi surgeri diseas free use continu intraven infus doxorubicin-dacarbazin compar bolu dose agent patient